Impact of Acetazolamide on Central Sleep Apnea Patients Receiving Medication for Opioid Use Disorder.

A clinical trial, NCT06521476, is being conducted to investigate the effects of acetazolamide on central sleep apnea (CSA) in individuals with opioid use disorder. The trial will randomly assign participants to receive either acetazolamide or a placebo for 7 days. The study aims to determine if acetazolamide can improve CSA and if this improvement leads to physiological changes that may reduce drug craving. Various measures, including breathing during sleep, sleep quality, anxiety, cognition, and drug craving, will be assessed. The trial is sponsored by the University of Pittsburgh and is being conducted in the United States, with collaboration from the National Institute on Drug Abuse. [Extracted from the article]